StockData
Silence Therapeutics plc logo

Silence Therapeutics plc (SLN) shareholders

SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$19.80+0.00 (0.00%)

Close on Nov 17, 2026Market cap $935.48MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
24M
Shares held, 13F filers
Institutional holders
72
20 new, 4 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Richard Ian Griffiths
Joint filing with Ora Capital Limited (13.60%)
34,543,30224.40%13D (active) amendmentJun 25, 2025
Richard Griffiths14,391,4987.97%13D (active) amendmentAug 12, 2026
FMR LLC
Joint filing with Abigail P. Johnson (7.10%)
13,180,2067.10%13G (passive)Sep 30, 2026
Raymond Debbane
Joint filing with Invus Public Equities, L.P. (6.10%), Invus Public Equities Advisors, LLC (6.10%) and 2 more
9,934,3147.00%13G (passive) amendmentJun 30, 2026
Tetragon Financial Management LP
Joint filing with Tetragon Financial Group Limited (5.30%), Patrick G. G. Dear (5.30%) and 1 more
9,878,5655.30%13G (passive) amendmentOct 5, 2026
Tetragon Financial Group Limited
Joint filing with Tetragon Financial Management LP (5.20%), Patrick G. G. Dear (5.20%) and 1 more
9,708,1535.20%13G (passive)Oct 5, 2026
Invus Public Equities Advisors, LLC
Joint filing with Invus Public Equities, L.P. (7.80%), Artal International S.C.A (7.80%) and 5 more
9,000,0007.80%13G (passive) amendmentDec 31, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SLNValueChange% of portfolio
Siren, L.L.C.3,311,438–$36.36M+400,0000.74%
TCG Crossover Management, LLC3,033,560–$33.31M–0.80%
Nantahala Capital Management, LLC2,693,462–$29.57M+546,7310.49%
Redmile Group, LLC2,164,777–$23.77M–1.60%
Citadel Advisors LLC1,329,625–$14.60M+94,8180.00%
Nextech Invest, Ltd.952,400–$10.46M–0.50%
Millennium Management LLC909,279–$9.98M−164,9120.00%
Ikarian Capital, LLC830,784–$1.83M−35,0000.20%
TFG Asset Management GP Ltd764,256–$8.39M+134,0951.32%
Soleus Capital Management, L.P.630,000–$6.92MNew0.24%
Balyasny Asset Management L.P.610,980–$6.71MNew0.01%
5AM Venture Management, LLC476,200–$5.23M–1.82%
Great Point Partners LLC450,000–$4.94M−570,4890.93%
Morgan Stanley403,172–$4.43M+337,6860.00%
Ameriprise Financial Inc370,052–$4.06MNew0.00%
Jane Street Group, LLC369,151–$4.05M+268,2240.00%
ADAR1 Capital Management, LLC338,373–$3.72M+166,2160.17%
SummitTX Capital, L.P.326,648–$3.59MNew0.09%
Schonfeld Strategic Advisors LLC269,348–$2.96MNew0.01%
UBS Group AG243,152–$2.67M−3,7850.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 20267224M20 / 2218 / 45M2M
Q1 20265620M6 / 2411 / 74M2M
Q4 20255818M14 / 1517 / 103M5M
Q3 20255420M6 / 1516 / 70M0M
Q2 20255520M9 / 1318 / 131M3M
Q1 20255922M6 / 1825 / 112M4M
Q4 20246525M16 / 2413 / 205M8M
Q3 20246928M13 / 2416 / 158M9M
Q2 20247129M12 / 2320 / 55M4M
Q1 20246428M32 / 1711 / 213M6M
Q4 20233421M8 / 96 / 22M1M
Q3 20232820M4 / 47 / 51M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

9 funds held SLN in Q2 2026, 82% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of SLNValue% of fundAs of
Fidelity Advisor Biotechnology Fund482,088–$5.06M0.23%Jul 31, 2026
iShares Biotechnology ETF185,777–$2.04M0.02%Jun 30, 2026
Alger Small Cap Growth Fund105,679–$1.11M0.54%Jul 31, 2026
Alger Small Cap Growth Institutional Fund41,292–$433.15K0.54%Jul 31, 2026
Fidelity Nasdaq Composite Index Fund29,538–$203.81K0.00%May 31, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF9,532–$104.66K0.01%Jun 30, 2026
ActivePassive International Equity ETF8,695–$60.00K0.01%May 31, 2026
Steward Values Enhanced International Fund5,800–$60.84K0.02%Jul 31, 2026
Invesco Nasdaq Biotechnology ETF2,476–$17.08K0.03%May 31, 2026
ProShares Ultra Nasdaq Biotechnology1,736–$11.98K0.02%May 31, 2026
Blackstone Alternative Multi-Strategy Fund1,000–$10.98K0.00%Jun 30, 2026
College Retirement Equities Fund - Total Global Stock Account24–$2640.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Rhonda Lynette HellumsChief Financial Officer, Director1,500Jan 6, 2026
Iain RossInterim PEO, Director39,942Dec 22, 2025
Craig A. ToomanPresident and CEO, Director33,486Jan 6, 2025
Steven J. RomanoEVP and Chief R&D Officer12,993Jan 6, 2026
James Ede-GolightlyDirector15,000Jan 6, 2026
Timothy McInerneyDirector–Jan 6, 2026
David LemusDirector7,527Jan 6, 2026
Michael H. DavidsonDirector12,993Jan 6, 2025
Richard Ian Griffiths10% owner–Aug 13, 2026

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
2M shares short
Days to cover
1.0
At 9M shares a day
Change since last report
-17.4%
From 3M shares
Short volume, 20 days
19.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Silence Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 20,509 shares on Sep 2, 2026 over the last 90 days.

See a number that looks wrong?